Genmab A/S’s (GMAB) “Buy” Rating Reaffirmed at HC Wainwright

Genmab A/S (NASDAQ:GMAB)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a research note issued on Wednesday,Benzinga reports. They presently have a $50.00 target price on the stock. HC Wainwright’s target price points to a potential upside of 125.43% from the stock’s current price.

GMAB has been the topic of several other reports. Redburn Atlantic assumed coverage on shares of Genmab A/S in a research note on Tuesday, October 8th. They set a “buy” rating on the stock. BMO Capital Markets reissued an “outperform” rating and set a $48.00 price objective (up previously from $46.00) on shares of Genmab A/S in a research report on Friday, November 8th. Morgan Stanley reaffirmed an “equal weight” rating and issued a $31.00 target price on shares of Genmab A/S in a research report on Wednesday, September 11th. Finally, Sanford C. Bernstein upgraded Genmab A/S from a “strong sell” rating to a “hold” rating in a report on Friday, December 20th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $45.20.

Genmab A/S Trading Up 1.5 %

GMAB stock opened at $22.18 on Wednesday. The firm has a market cap of $14.68 billion, a PE ratio of 21.53, a price-to-earnings-growth ratio of 0.63 and a beta of 0.97. The stock has a 50-day moving average price of $21.33 and a 200-day moving average price of $24.28. Genmab A/S has a 1-year low of $19.85 and a 1-year high of $32.88.

Genmab A/S (NASDAQ:GMAB) last issued its earnings results on Wednesday, November 6th. The company reported $0.29 earnings per share for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.03). The business had revenue of $816.10 million during the quarter, compared to the consensus estimate of $838.20 million. Genmab A/S had a return on equity of 14.64% and a net margin of 23.49%. During the same quarter in the previous year, the firm posted $0.47 earnings per share. On average, analysts forecast that Genmab A/S will post 1.28 earnings per share for the current year.

Hedge Funds Weigh In On Genmab A/S

Several large investors have recently added to or reduced their stakes in the business. Legacy Wealth Asset Management LLC raised its stake in shares of Genmab A/S by 1.1% in the third quarter. Legacy Wealth Asset Management LLC now owns 44,979 shares of the company’s stock worth $1,097,000 after purchasing an additional 471 shares during the last quarter. Benjamin F. Edwards & Company Inc. grew its holdings in Genmab A/S by 7.1% during the second quarter. Benjamin F. Edwards & Company Inc. now owns 7,227 shares of the company’s stock worth $182,000 after buying an additional 478 shares in the last quarter. GAMMA Investing LLC raised its position in Genmab A/S by 96.6% in the 4th quarter. GAMMA Investing LLC now owns 2,139 shares of the company’s stock valued at $45,000 after buying an additional 1,051 shares during the last quarter. Eagle Asset Management Inc. lifted its stake in Genmab A/S by 10.0% during the 3rd quarter. Eagle Asset Management Inc. now owns 12,356 shares of the company’s stock valued at $285,000 after acquiring an additional 1,121 shares in the last quarter. Finally, Rhumbline Advisers boosted its holdings in Genmab A/S by 7.1% during the 2nd quarter. Rhumbline Advisers now owns 18,694 shares of the company’s stock worth $470,000 after acquiring an additional 1,236 shares during the last quarter. Institutional investors own 7.07% of the company’s stock.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.